---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-001072"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2021-08-09T23:59:59+00:00"
generated_at: "2026-06-29T18:24:58.496861+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q2 net loss widens to $55.9M; KSI-301 trials on track for data in early 2022

## Summary
- Net loss of $55.9M ($1.08/share) vs $26.0M ($0.58) in Q2 2020; R&D expenses rose to $45.4M.
- Cash and equivalents $880.9M; royalty financing from BBA capped at $450M after second $125M tranche not paid.
- Phase 3 wet AMD DAZZLE study on track topline data Q1 2022; enrollment in BEACON, GLEAM, GLIMMER, DAYLIGHT ongoing.
- China IND approved for KSI-301 in RVO and DME; first patients expected in 2021.
- Proposed INN for KSI-301 is tarcocimab tedromer; GLOW study in non-proliferative DR to start August 2021.

## SEC filing metadata
- accession: 0000950170-21-001072
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2021-08-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/0000950170-21-001072-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017021001072/kod-20210809.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-001072
- JSON: https://secwatch.observer/filing/0000950170-21-001072.json
- Plain text: https://secwatch.observer/filing/0000950170-21-001072.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.